Citations

Clear

3042 citation(s) found for "Kumar, S".

A systematic review and meta-analysis of cardiac resynchronization therapy in inotrope-dependent heart failure: an update
Bray, Johnathan J., D’Ascenzo, F., Duffy, Edward, Hewett, John E., Adegbie, Divine , Patel, Niket , Haq, Ikram-Ul , Ahmed, M , Bray, Jonathan James Hyett , Al-Shakarchi, Nader , Ho, Jamie Sin Ying , Hewett, J, Khan, F, Kumar, Navin , Patel, N

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.1022 Get It

Abstract Background Inotrope-dependent heart failure (HF) carries a poor prognosis. Advanced mechanical supports have been viewed as primary treatment modalities for these patients, but cardiac resynchronization therapy (CRT) is an emerging alternative. Whether CRT is viable in HF patients who require inotropic support is uncertain. Purpose To assess outcomes of CRT in end-stage inotrope-dependent HF. Methods Following PRISMA guidelines, we searched Medline, EMBASE, Scopus, and Cochrane Library until December 31st 2022, with the following terms: "end-stage heart failure," "catecholamine-dependent overt heart failure," "inotrope-dependent heart failure," "advanced heart failure," "New York Heart Association class IV," "NYHA class IV." These terms were combined with "cardiac resynchronization therapy" OR "CRT" OR "biventricular device". Studies were included if: 1) HF patients required on inotropic support at CRT implantation; 2) patients were at least 18 years old; and 3) provided a clear definition of "inotrope dependence" or "inability to wean." A meta-analysis with random effects was performed in R (Version 3.5.1) with data presented as mean ± standard error. Results 19 studies comprised of 386 inotrope-dependent HF patients (mean age 64.4 ± 1.2 years, 76.9% male, 54.6% non-ischemic cardiomyopathy, mean QRS duration 168.0 ± 4.6 ms, mean follow-up 778 ± 110.7 days) were included for meta-analysis. A large majority of patients survived until discharge at 90% (95% CI: 81.0%-96.8%, I2=51%, p=0.04, Figure 1A), 88.6% were weaned off inotropes (95% CI: 77.5%-96.8%, I2=64%, p<0.01), and mean time to discharge post-CRT was 7.8 days (95% CI: 3.9-11.7, I2= 84%, p<0.01). After one year of follow-up 69.5% survived (95% CI: 59.2%-78.9%, I2=53%, p=0.02, Figure 1B) and 59.1% (95% CI: 50.1%-67.8%, I2=58%, p<0.01, Figure 1C) were alive at the end of follow-up. During follow-up the mean number of hospital admission for HF was reduced by 1.87 (95% CI: 2.70-1.04, I2=77%, p=0.04). Post-CRT mean QRS duration was reduced by 29.0 ms (95% CI: 41.33-16.68, I2=69%, p=0.006, Fig) and mean left ventricular ejection fraction increased by 4.83% (95% CI: 3.09%-6.57%, I2=16%, p=0.31, Fig). The mean NYHA class post-CRT was 2.7 (95% CI: 2.5-3.0, I2=56%, p=0.03, Figure 2A), 39.6% (95% CI: 18,.7%-62.3%, I2=83%, p<0.01, Figure 2C) improved to NYHA class III and 34.6% (95% CI: 16.4%-55.2%, I2=79%, p<0.01, Figure 2D) improved to NYHA class II. Responders to CRT tended be male (85.7% vs. 40%, p=0.015), have a history of left bundle branch block (71.4% vs. 30%, p=0.036) or an increased left ventricular end-diastolic volume (274.3 mL vs. 225.9 mL, p=0.038). Conclusion(s) Our results suggest that CRT is an alternative option for end-stage inotrope-dependent HF, improving survival, NYHA status, and HF readmission. CRT responders appear to be male with evidence of preserved diastolic function or a history of a left bundle branch block.
Burden and impact of comorbid depression on in-hospital outcomes of Hypertrophic Cardiomyopathy patients in the USA: a nationwide analysis, 2020
Bhanushali, Aditi , Sampath, Sangeetha , Ahmed, Hafeezuddin , Mohammed, Adil Sarvar , Ganampet, Narendranath Reddy , Muslehuddin, Zainab , Bandaru, Ravi , Allamneni, Rakesh , Behera, Arunanshu , Adompreh-Fia, K O K O U, Mohammed, Adil Sarvar , Sampath, S, Bandaru, R, Behera, A, Kumar, Shruti A , Adompreh-Fia, Kokou Selom , Desai, Rupak

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.614 Get It

Abstract Background Depression has emerged as a critical risk factor for development and progression of various cardiovascular diseases; however, the association between depression and Hypertrophic Cardiomyopathy (HCM) outcomes is less clear. We aimed to determine the impact of comorbid depression on patients hospitalized with HCM. Methods The National Inpatient Sample (2020) was assessed to identify patients hospitalized with HCM using relevant ICD-10 codes. Propensity score matching of 1:1 was performed and the cohort was divided into two - those with comorbid depression (HCM-D+) and those without (HCM-D-). Baseline characteristics and comorbidities were compared between the two cohorts. Impact of comorbid depression on hospitalized HCM patients was evaluated using a multivariate regression analysis adjusting for confounders. Results We identified a cohort of 15530 in-hospital HCM patients with a median age of 67 years (66.9% females, 33.1% males, 74.6% whites, 19.1% blacks, 4.3% hispanics, 1.7% Asians). Amongst 15530, 85.5% admissions were non-elective. The HCM-D+ cohort had significantly higher rates of comorbidities such as hypertension (76.4% vs 71.4%), hyperlipidemia (62.5% vs 52.4%), obesity (27.9% vs 24.9%), smoking (28.1% vs 25.7%), dementia (8.2% vs 4.4%) and cancer (7.5% vs 5.8%) (p<0.001). When in-hospital outcomes were compared, HCM-D+ cohort paradoxically appeared to have 44% lower risk of all-cause mortality (OR-0.56; 95%CI: 0.37- 0.84), 22% lower risk of composite end points (all-cause mortality, heart failure, atrial fibrillation, cardiac arrest including ventricular fibrillation, acute ischemic stroke) (OR-0.78; 95%CI:0.66-0.91), 21% lower risk of atrial fibrillation alone (OR-0.79; 95%CI:0.67-0.92) (p<0.001). Conclusion Despite having higher rates of comorbidities, comorbid depression in HCM patients appeared to improve in-hospital outcomes. Further studies are needed to uncover the paradoxical protection provided by underlying depression.
Risk stratification of coronary artery disease using the artificial intelligence-enabled electrocardiogram
Sachadeva, N, Abbou, R , Gupta, Yogesh Kumar , Anto, Aneesha C, Asfahan, Shahir , Hegstrom, Lars , McCully, Robert B. , Friedman, Paul A. , Soundararajan, V., Lopez-Jiminez, F, Awasthi, Samir , Gupta, Y, Alger, Heather M. , Medina‐Inojosa, José R. , Lerman, Amir , Attia, Zachi I. , Soundararajan, V

Mayo Clinic

European Heart Journal | November 11, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.2935 Get It

Abstract Background Atherosclerotic cardiovascular disease (ASCVD), of which coronary artery disease (CAD) is the primary manifestation, is the leading cause of death worldwide. The AHA/ACC Pooled Cohort Equation (PCE) facilitates risk stratification and initiation of primary prevention of ASCVD, however their performance is suboptimal. Purpose We develop an artificial intelligence-based electrocardiogram (ECG) analysis (AI-ECG) algorithm to detect different stages of CAD and assessed the value of AI-ECG over PCE to predict incident myocardial infarction (MI) and survival over 3-years. Methods Using electronic health record data from approximately 7 million patients seen at over 70 hospitals and clinics across 5 states in the USA, we created independent AI-ECG models to identify elevated coronary artery calcium (CAC) by computer tomography, the presence of obstructive CAD by stress test or angiography, and left ventricular regional akinesis by echocardiogram, presumed to represent prior MI. Deep structured data, AI-enabled natural language processing of unstructured data were used to ensure cohort, and physician review of labeling were used to ensure cohort accuracy. These models were ensembled into a single model that was used to assess the utility of AI-ECG for predicting new occurrence MI in PCE- and age-stratified cohorts of patient with no prior history of ASCVD, over a 3-year timeframe using Cox’s proportional hazards analysis. Results A total of 6,080 patients (15,192 ECGs) were labeled positive for CAC ≥ 300, 12,561 patients (18,915 ECGs) positive for obstructive CAD, and 10,767 patients (23,870 ECGs) positive for regional akinesis. AI-ECG for identifying elevated CACS, obstructive CAD, and regional akinesis achieved AUROCs of 0.86, 0.80, and 0.93, respectively. All AI-ECG models identified increased 3-year risk for MI and death in AI-ECG positive versus AI-ECG negative patients and subgroups with 2 or 3 positive results had stepwise increased risk (Figure A). In a 3-year survival analysis of all-comer patients, the hazard ratio for those that tested positive on 1, 2, or 3 versus 0 positive disease-specific models were 1.61 (1.53-1.69). 2.40 (2.27-2.55), 3.42 (3.21-3.65), respectively. Risk stratification was also observed in cohorts without prior ASCVD stratified by low and high PCE-derived 10-year ASCVD risk (Figure B) and in cohorts stratified by age, including under the age of 40. Conclusions AI-ECG has potential to address unmet need for accessible risk stratification in patients in whom PCE under, over, or insufficiently estimate ASCVD risk, and in whom risk assessment over periods of time shorter than 10 years is desired.
Role of soluble urokinase type plasminogen activator receptor (suPAR) in predicting mortality, readmission, length of stay and discharge in emergency patients: A systematic review and meta analysis
Rehan, Syeda Tayyaba , Ali, Eman , Ali, Gibran, Asghar, Muhammad Sohaib , Asghar, Muhammad S , Hussain, Hassan ul , Ali, Eman , Kumar, Kanwal Ashok , Tabassum, Shehroze , Hasanain, Muhammad , Shaikh, Asim Jamal , Yousaf, Zohaib

Mayo Clinic

Medicine | November 10, 2023 | Volume: 102 | Issue: 45 | Pages: e35718

10.1097/md.0000000000035718 | PMID 37960735 Get It

Background: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory biomarker that is used to predict mortality, readmission, early discharge, and LOS, thus, serves as a useful tool for ED physicians. Our study aims to analyze the efficacy of suPAR in predicting these prognostic markers in ED. Methods: We performed a comprehensive search on 6 databases from the inception to 30th November 2022, to select the following eligibility criteria; a) observation or triage trial studies investigating the role of suPAR levels in predicting: 30 day and 90-day mortality, 30-day readmission, early discharge (within 24hr), and LOS in patients coming to AMU. Results: A total of 13 studies were included, with a population size of 35,178, of which 52.9% were female with a mean age of 62.93 years. Increased risk of 30-day mortality (RR = 10.52; 95% CI = 4.82–22.95; I2 = 38%; P < .00001), and risk of 90-day mortality (RR = 5.76; 95% CI = 3.35–9.91; I2 = 36%; P < .00001) was observed in high suPAR patients. However, a slightly increased risk was observed for 30-day readmission (RR = 1.50; 95% CI = 1.16–1.94; I2 = 54%; P = .002). More people were discharged within 24hr in the low suPAR level group compared to high suPAR group (RR = 0.46; 95% CI = 0.40–0.53; I2 = 41%; P < .00001). LOS was thrice as long in high suPAR level patients than in patients with low suPAR (WMD = 3.20; 95% CI = 1.84–4.56; I2 = 99%; P < .00001). Conclusion: suPAR is proven to be a significant marker in predicting 30-day and 90-day mortality in ED patients.
A phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases
Schlembach, Pamela J., Bowers, John, McAleer, Mary Frances , Brown, Paul D. , Gopal, Ramesh, Wiederhold, Lee, Swanson, Todd A. , Li, Jing , Ferguson, Sherise D. , Philip, Nancy V, DeGracia, Lilybeth, Bloom, Elizabeth S., Chun, Stephen G , Garg, Amit Kumar , Hernández, Mike , Shah, Shalin J. , Philip, Nancy V., Chun, Stephen G.

Mayo Clinic

JNCI Cancer Spectrum | November 9, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/jncics/pkad093 | PMID 37944053 Get It

Abstract Stereotactic radiation therapy yields high rates of local control for brain metastases, but patients in rural or suburban areas face geographic and socioeconomic barriers to its access. We conducted a phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases in an integrated academic satellite network for patients 18 years of age or older with 4 or fewer brain metastases. Dose was based on gross tumor volume: less than 3.0 cm, 27 Gy in 3 fractions and 3.0 to 3.9 cm, 30 Gy in 5 fractions. Median follow-up was 10 months for 73 evaluable patients, with a median age of 68 years. Median intracranial progression-free survival was 7.1 months (95% confidence interval = 5.3 to not reached), and median survival was 7.2 months (95% confidence interval = 5.4 to not reached); there were no serious adverse events. Outcomes of this trial compare favorably with contemporary trials, and this treatment strategy provides opportunities to expand stereotactic radiation therapy access to underserved populations.
Endoscopic diagnosis and prevalence of early gastric cancer in India: A prospective study
Mohapatra, Ashutosh, Mohapatra, Sonmoon , Mahawar, Shruti, Pani, Krushna Chandra, Mohapatra, Nachiketa, Ramchandani, Mohan , Reddy, D. Nageshwar , Goenka, Mahesh Kumar , Uedo, Noriya , Goenka, Mahesh K

Mayo Clinic

DEN Open | November 4, 2023 | Volume: 4 | Issue: 1 | Pages: No page available

10.1002/deo2.309 | PMID 37927951 Get It

AbstractObjectivesAlthough countries like Japan and South Korea have implemented nationwide endoscopic screening programs, there is limited evidence on the effectiveness of endoscopy for diagnosing early gastric cancer (EGC) in developing countries such as India. In the present study, we aimed to determine the feasibility of endoscopic detection of EGC from India.MethodsThe data was prospectively collected for all patients ≥40 years who underwent a diagnostic upper endoscopy from April to September 2021. A single endoscopist who performed the endoscopic procedures completed 1‐month training in advanced endoscopy in Japan. Following the training, the endoscopist continued to engage in internet‐based discussions regarding his cases encountered. Prior to this training, the endoscopist had not detected any EGC cases during his 12‐year gastroenterology practice.ResultsA total of 1033 patients were included in the study, with males accounting for 65.4% and a mean age 52 years. The average procedural time was 7.13 ± 4.8 min. A total of 25 patients (2.4%) were found to have GC, including 6 patients (0.6%) with EGC. Two patients had synchronous EGC lesions. All EGC patients were males, with an average age of 66 years. All EGCs were detected in the distal stomach in the presence of Helicobacter pylori infection and severe atrophic gastritis.ConclusionOur findings showed that the endoscopic detection of EGC is feasible in India. Optimal training on endoscopic diagnosis of EGC can improve the detection of such lesion. Further studies are warranted to assess the optimization and implementation of an endoscopic screening program for EGC in India.
From Consensus to Validation: A Multicenter Study for Design and Development of a Holmium Laser Enucleation of the Prostate Hydrogel Simulation Platform
Shepard, Lauren , Schuler, Nathan , Narang, Gopal , Humphreys, Mitchell R. , Krambeck, Amy E. , Humphreys, Mitchell, Setia, Shaan A. , Das, Akhil Kumar , Miller, Nicole L. , Ghazi, Ahmed

Mayo Clinic

Journal of Endourology | November 2, 2023 | Volume: 38 | Issue: 1 | Pages: 60-67

10.1089/end.2023.0430 | PMID 37917099 Get It

Saphenous Vein Tributaries in Sequential Vein Grafting for Coronary Artery Disease
Lanka, Santh Prakash , Rai, Guruprasad , Maramreddy, Revanth , Bishnoi, Arvind Kumar , Kumara, V. M. Ruvin, Sevagur, Ganesh Kamath, Kumara, Vijay

Mayo Clinic

No container title available | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3507838/v1 Get It

Abstract Background Sequential vein grafting is utilized to revascularize multiple distal vascular territories in patients with diffusely diseased coronaries undergoing repeat coronary artery bypass grafting (CABG). However, sequential vein grafting is technically challenging due to the side-to-side anastomosis. This study expands on the usage of saphenous vein tributaries in sequential vein grafting (tributary technique) and its outcomes at a single institution. Methods A retrospective observational chart review was conducted on patients who underwent the proposed technique in our institution over three years. The primary outcome variables included all-cause mortality and freedom from major adverse cardiovascular events (MACE). A descriptive analysis was conducted to express the continuous variables as mean and standard deviation and categorical variables as frequency and percentages. Results The study included 187 patients with a mean follow-up duration of 24.8 ± 10.0 months and operative mortality of 1.7%. A total of 131 patients remained symptom-free starting from the date of surgery, and four cardiovascular mortalities were reported during the follow-up period. Conclusion The tributary technique is feasible and can be a potential option in repeat CABGs requiring multiple grafts in patients with adequate vein calibre in lower limbs.
Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia
Shah, Rushi , Polen-De, Clarissa , McGree, Michaela E. , Fought, Angela J. , Kumar, Amanika , McGree, Michaela, Fought, Angela, Kumar, Amanika

Mayo Clinic

Current Oncology | October 27, 2023 | Volume: 30 | Issue: 11 | Pages: 9501-9513

10.3390/curroncol30110688 | PMID 37999108 Get It

We investigated the impact of sarcopenia on adjuvant chemotherapy dosing in advanced epithelial ovarian cancer (EOC). The chemotherapy dosing and toxicity of 173 eligible patients who underwent cytoreductive surgery and adjuvant chemotherapy at a single institution were analyzed. Patients with a skeletal muscle index less than 39 cm2/m2 measured on a CT scan were considered sarcopenic. Sarcopenic and non-sarcopenic patients were compared with regard to relative dose intensity (RDI), completion of scheduled chemotherapy, toxicity, and survival. A total of 62 (35.8%) women were sarcopenic. Sarcopenic women were less likely to complete at least six cycles of chemotherapy (83.9% vs. 95.5%, p = 0.02). The mean RDI for both carboplatin (80.4% vs. 89.4%, p = 0.03) and paclitaxel (91.9% vs. 104.1%, p = 0.03) was lower in sarcopenic patients compared to non-sarcopenic patients. Despite these differences in chemotherapy, there was no difference in neutropenia or median overall survival (3.99 vs. 4.57 years, p = 0.62) between the sarcopenic and non-sarcopenic women, respectively. This study highlights the importance of considering lean body mass instead of body weight or surface area in chemotherapy dosing formulas for sarcopenic women with advanced EOC. Further research is needed to optimize chemotherapy strategies based on individual body composition, potentially leading to improved dosing strategies in this population.
SLAM (CD150) receptor homologous peptides block the peste des petits ruminants virus entry into B95a cells
Agrawal, Aditya , Varshney, Rajat , Gattani, Anil , Kirthika, Perumalraja , Gupta, Rohini , Kirthika, Perumalraja , Kumar, Deepak , Singh, Rabindra Prasad , Singh, Praveen

Mayo Clinic

Proteins: Structure, Function, and Bioinformatics | October 26, 2023 | Volume: 92 | Issue: 3 | Pages: 356-369

10.1002/prot.26595 | PMID 37881117 Get It

AbstractThe fusion of haemagglutinin‐neuraminidase (HN) protein of peste des petits ruminant (PPR) virus with signaling lymphocyte activation molecules (SLAM) host cell receptor consequences the virus entry and multiplication inside the host cell. The use of synthetic SLAM homologous peptides (i.e., molecular decoy for HN protein of PPR virus) may check PPR infection at the preliminary stage. Hence, the predicted SLAM homologous peptides using bioinformatics tools were synthesized by solid phase chemistry with standard Merrifield's 9‐fluorenylmethoxycarbonyl (Fmoc) chemistry and were purified by reverse phase high performance liquid chromatography. The secondary structures of synthesized peptides were elucidated by circular dichroism spectroscopy. The in vitro interactions of these peptides were studied through indirect Enzyme Linked Immuno Sorbent Assay (ELISA) and visual surface plasmon UV‐visible spectroscopy. The SLAM homologous peptides were able to interact with the peste des petits ruminant virus (PPRV) with varying binding efficiency. The interaction of SLAM homologous peptide with the PPR virus was ascertained by the change in the plasmon color from red wine to purple during visual detection and also by bathochromic shift in absorbance spectra under UV‐visible spectrophotometry. The cytotoxic and anti‐PPRV effect of these peptides were also evaluated in B95a cell line using PPR virus (Sungri/96). The cytotoxic concentration 50 (CC50) value of each peptide was greater than 1000 μg mL−1. The anti‐PPRV efficiency of SLAM‐22 was relatively high among SLAM homologous peptides, SLAM‐22 at 25 μg mL−1 concentration showed a reduction of more than log10 3 virus titer by priming of B95a cell line while the use of SLAM‐15 and Muco‐17 at the same concentration dropped virus titer from log10 4.8 to log10 2.5 and log10 3.1 respectively. The concentration of SLAM homologous peptide (25 μg mL−1) to exert its anti‐PPRV effect was much less than its CC50 level (>1000 μg mL−1). Therefore, the synthetic SLAM homologous peptides may prove to be better agents to target PPRV.